Literature DB >> 12704655

Nuclear translocation of insulin receptor substrate-1 by the insulin receptor in mouse embryo fibroblasts.

An Wu1, Laura Sciacca, Renato Baserga.   

Abstract

Translocation of the insulin receptor substrate-1 (IRS-1) to the nuclei has been reported to occur in cells stimulated by insulin-like growth factor-1 (IGF-I) or expressing certain viral and cellular oncogenes. We show here that insulin can also induce nuclear translocation of IRS-1 in mouse embryo fibroblasts (MEF), that do not express the type 1 insulin-like growth factor receptor (IGF-IR). Only the A isoform of the insulin receptor (IR) can induce IRS-1 nuclear translocation, which is significant when the receptor is over-expressed. At physiological receptor levels, translocation occurs only in a fraction of cells, and only at high concentrations of ligand. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704655     DOI: 10.1002/jcp.10261

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  BCR/ABL stimulates WRN to promote survival and genomic instability.

Authors:  Artur Slupianek; Tomasz Poplawski; Stanislaw K Jozwiakowski; Kimberly Cramer; Dariusz Pytel; Ewelina Stoczynska; Michal O Nowicki; Janusz Blasiak; Tomasz Skorski
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

Review 2.  Nuclear IRS-1 and cancer.

Authors:  Krzysztof Reiss; Luis Del Valle; Adam Lassak; Joanna Trojanek
Journal:  J Cell Physiol       Date:  2012-08       Impact factor: 6.384

3.  IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors.

Authors:  Lauren M Rota; Lidia Albanito; Marcus E Shin; Corey L Goyeneche; Sain Shushanov; Emily J Gallagher; Derek LeRoith; Deborah A Lazzarino; Teresa L Wood
Journal:  Cancer Res       Date:  2014-08-04       Impact factor: 12.701

4.  IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype.

Authors:  Guido T Bommer; Ying Feng; Ayaka Iura; Thomas J Giordano; Rork Kuick; Hüseyin Kadikoy; Deanna Sikorski; Rong Wu; Kathleen R Cho; Eric R Fearon
Journal:  J Biol Chem       Date:  2009-10-20       Impact factor: 5.157

Review 5.  Insulin Receptor Isoforms in Physiology and Disease: An Updated View.

Authors:  Antonino Belfiore; Roberta Malaguarnera; Veronica Vella; Michael C Lawrence; Laura Sciacca; Francesco Frasca; Andrea Morrione; Riccardo Vigneri
Journal:  Endocr Rev       Date:  2017-10-01       Impact factor: 19.871

6.  Nuclear translocation of 3'-phosphoinositide-dependent protein kinase 1 (PDK-1): a potential regulatory mechanism for PDK-1 function.

Authors:  Mei A Lim; Chintan K Kikani; Michael J Wick; Lily Q Dong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-17       Impact factor: 11.205

7.  The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer.

Authors:  Diana L Esposito; Federica Aru; Rossano Lattanzio; Annalisa Morgano; Michela Abbondanza; Reza Malekzadeh; Faraz Bishehsari; Rosa Valanzano; Antonio Russo; Mauro Piantelli; Antonio Moschetta; Lavinia Vittoria Lotti; Renato Mariani-Costantini
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

8.  Molecular basis of signaling specificity of insulin and IGF receptors: neglected corners and recent advances.

Authors:  Kenneth Siddle
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-28       Impact factor: 5.555

9.  Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.

Authors:  Cecilia Garofalo; Mariantonietta Capristo; Caterina Mancarella; Hadas Reunevi; Piero Picci; Katia Scotlandi
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-13       Impact factor: 5.555

10.  Proline-rich tyrosine kinase 2 (Pyk2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells.

Authors:  Marco Genua; Shi-Qiong Xu; Simone Buraschi; Stephen C Peiper; Leonard G Gomella; Antonino Belfiore; Renato V Iozzo; Andrea Morrione
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.